Global experience of faricimab in clinical settings - a review

References

• Sharma A, Kumar N, Kuppermann BD, et al. Faricimab: expanding horizon beyond VEGF. Eye (Lond). 2020 May;34(5):802–804. doi: 10.1038/s41433-019-0670-1
   PubMed Web of Science ®Google Scholar
• Rush RB, Rush SW. Intravitreal faricimab for aflibercept-resistant neovascular age-related macular degeneration. Clin Ophthalmol. 2022 Dec 9;16:4041–4046. doi: 10.2147/OPTH.S395279
   PubMed Web of Science ®Google Scholar
• Rush RB. One-year outcomes of faricimab treatment for aflibercept-resistant neovascular age-related macular degeneration. Clin Ophthalmol. 2023 Aug 1;17:2201–2208. doi: 10.2147/OPTH.S424315
   PubMed Web of Science ®Google Scholar
• Cheng AM, Joshi S, Banoub RG, et al. Faricimab effectively resolves intraretinal fluid and preserves vision in refractory, recalcitrant, and nonresponsive neovascular age-related macular degeneration. Cureus. 2023 Jun 7;15(6):e40100.
   PubMed Web of Science ®Google Scholar
• Leung EH, Oh DJ, Alderson SE, et al. Initial real-world experience with faricimab in treatment-resistant neovascular age-related macular degeneration. Clin Ophthalmol. 2023 May 5;17:1287–1293.
   PubMed Web of Science ®Google Scholar
• Khanani AM, Aziz AA, Khan H, et al. The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study - 6 month results. Eye (Lond). 2023;37(17):3574–3581. doi: 10.1038/s41433-023-02553-5
   PubMed Web of Science ®Google Scholar
• Mukai R, Kataoka K, Tanaka K, et al. Three-month outcomes of faricimab loading therapy for wet age-related macular degeneration in Japan. Sci Rep. 2023 May 30;13(1):8747. doi: 10.1038/s41598-023-35759-4
   PubMed Web of Science ®Google Scholar
• Kishi M, Miki A, Kamimura A, et al. Short-term outcomes of faricimab treatment in aflibercept-refractory eyes with neovascular age-related macular degeneration. J Clin Med. 2023 Aug 6;12(15):5145. doi: 10.3390/jcm12155145
   PubMed Web of Science ®Google Scholar
• Szigiato A, Mohan N, Talcott KE, et al. Short-term outcomes of faricimab in patients with neovascular age-related macular degeneration on prior anti-VEGF therapy. Ophthalmol Retina Sep. 2023;9:S2468–6530(23)00437–2.
   Google Scholar
• Kataoka K, Itagaki K, Hashiya N, et al., for Japan AMD Research Consortium (JARC) Six-month outcomes of switching from aflibercept to faricimab in refractory cases of neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2024 Jan;262(1):43–51. doi: 10.1007/s00417-023-06222-x
   PubMed Web of Science ®Google Scholar
• Rush RB, Rush SW. Faricimab for treatment-resistant diabetic macular edema. Clin Ophthalmol. 2022 Aug 24;16:2797–2801. doi: 10.2147/OPTH.S381503
   PubMed Web of Science ®Google Scholar
• Rush RB. One year results of faricimab for aflibercept-resistant diabetic macular edema. Clin Ophthalmol. 2023 Aug 16;17:2397–2403. doi: 10.2147/OPTH.S424314
   PubMed Web of Science ®Google Scholar
• Kusuhara S, Kishimoto-Kishi M, Matsumiya W, et al. Short-term outcomes of intravitreal faricimab injection for diabetic macular edema. Medicina. 2023;59(4):665. doi:10.3390/medicina59040665
   PubMedGoogle Scholar
• Ohara H, Harada Y, Hiyama T, et al. Faricimab for Diabetic Macular Edema in Patients Refractory to Ranibizumab or Aflibercept. Medicina (Kaunas). 2023 Jun 11;59(6):1125.
   PubMed Web of Science ®Google Scholar
• Ghoraba HH, DeBoer C, Moshfeghi DM. Rapid Improvement in lipid maculopathy following faricimab therapy in recalcitrant familial exudative vitreoretinopathy. Ophthalmic Surg Lasers Imaging Retina. 2023 Jul;54(7):426–428. doi: 10.3928/23258160-20230609-01
   PubMed Web of Science ®Google Scholar
• Clemens CR, Alten F, Zimmermann JA, et al. Old problem in a New Guise: retinal pigment epithelium tear after intravitreal faricimab (Vabysmo®) injection. Case Rep Ophthalmol. 2023 May 26;14(1):241–244.
   PubMedGoogle Scholar
• Schönbach EM, Freeman WR. Choroidal detachment after intravitreal injection of Faricimab. JAMA Ophthalmol. 2023;141(9):e231067. doi:10.1001/jamaophthalmol.2023.1067
   PubMed Web of Science ®Google Scholar
• Heier JS, Khanani AM, Quezada Ruiz C, et al. Tenaya and Lucerne investigators. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022 Feb 19;399(10326):729–740. doi: 10.1016/S0140-6736(22)00010-1
   PubMed Web of Science ®Google Scholar
• Wykoff CC, Abreu F, Adamis AP, et al. Yosemite and Rhine investigators. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet. 2022 Feb 19;399(10326):741–755. doi: 10.1016/S0140-6736(22)00018-6
   PubMed Web of Science ®Google Scholar